BioNTech vaccine will likely work on UK variant, company's CEO says
BioNTech CEO Ugur Sahin is confident that the pharmaceutical company's coronavirus vaccine will work against the new U.K. variant of the virus.
"We don't know at the moment if our vaccine is also able to provide protection against this new variant," Sahin told a news conference Tuesday, after the vaccine was approved for use in the European Union. "But scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variants."
He explained that the proteins on the U.K. variant are 99% the same as the ones on the original strain, so BioNTech has "scientific confidence" that its vaccine will be effective on the variant as well.
Still, more studies need to be done.
"But we will know it only if the experiment is done and we will need about two weeks from now to get the data," Sahin said. "The likelihood that our vaccine works ... is relatively high."